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Aortic aneurysms secrete interleukin-6 into
the circulation
Joe Dawson, MRCS, Gillian W. Cockerill, PhD, Edward Choke, MRCS, Anne-Maria Belli, FRCR,
Ian Loftus, MD, FRCS, and Matt M. Thompson, MD, FRCS, London, United Kingdom
Objective: Circulating plasma interleukin-6 (IL-6) concentrations are elevated in patients with abdominal aortic aneu-
rysms (AAAs) compared with controls. In vitro studies suggest that the aneurysm is the source of the IL-6. Because IL-6
is an independent risk factor for cardiovascular mortality, elevation of this cytokine may be significant in these patients,
who represent a group at increased risk from cardiovascular death. The aim of this study was to directly measure in vivo
aortic IL-6 concentrations, testing the hypothesis that aneurysms secrete IL-6 into the circulation.
Methods: Before endovascular aneurysm repair took place, blood was sampled from the entire length of the aorta in 27
patients with AAA and nine with thoracic aneurysms (TAs). A control group consisted of 15 patients without aneurysms
undergoing angiography. Plasma IL-6 was determined using enzyme-linked immunosorbent assay, and high-sensitivity
C-reactive protein (hs-CRP) was measured turbidimetrically. Aneurysm surface area was calculated from axial computed
tomography scans.
Results:Mean IL-6 concentrations (pg/mL) were higher in the TA and AAA groups compared with controls (10.4 3.7
and 4.9  0.5 vs 2.7  0.5, P  .002). There was a significant difference in plasma IL-6 concentration corresponding to
aneurysm position in the AAA (P  .002) and TA (P  .008) groups, with both patterns conforming to a linear trend.
This pattern was not observed in the control group, in which no significant difference in IL-6 concentrations was found
throughout the aorta. Peak IL-6 occurred earlier in TAs compared with AAAs (descending aorta vs iliac artery)
corresponding to aneurysm position (P  .0007). Linear regression revealed a positive correlation between aneurysm
surface area and mean plasma IL-6 (Spearman’s correlation, P  .003). The mean surface areas of the TAs, at 0.07 m2
(interquartile range [IQR], 0.06 to 0.09), were higher than those of the AAAs at 0.03 m2 (IQR, 0.02 to 0.04; P .002).
High-sensitivity CRP was within normal limits, and no significant differences were found between the AAA group and
the controls.
Conclusions: Circulating IL-6 is elevated within the aorta in patients with aneurysms and corresponds to aneurysm
position. Furthermore, aneurysm surface area and mean plasma IL-6 are correlated. In the absence of any evidence of
systemic inflammation in the form of elevated hs-CRP, these data support the hypothesis that aneurysms secrete IL-6 into
the circulation. This may contribute to the high cardiovascular mortality observed in patients with aneurysms. (J Vasc
Surg 2007;45:350-6.)
Clinical Relevance: Abdominal aortic aneurysms (AAAs) are characterized histologically by widespread inflammation,
with IL-6 playing a central role. IL-6 is secreted by AAAs in vitro, and elevated IL-6 is an independent risk factor for
cardiovascular mortality. This may be clinically important in this group of patients with significant comorbidities at high
risk of cardiovascular death. This study supports the hypothesis that aneurysms secrete IL-6 into the systemic circulation
and suggests that the aneurysms may have more insidious effects upon cardiovascular health than solely that of rupture.Inflammation has emerged as a key process in the
pathogenesis of abdominal aortic aneurysms (AAAs).1,2
This has encouraged elucidation of the role of inflamma-
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350tory cytokines in aneurysm disease. The current paradigm
of aneurysm development suggests that inflammatory cells
within the wall of the aneurysm produce cytokines that
stimulate proteolytic enzymes such matrix metalloprotein-
ases.3 These enzymes promote the activation and release of
subsequent cytokines, perpetuating a vicious cycle of
chronic inflammation and extracellular matrix degradation
that is the pathologic hallmark of aneurysms.4
The multifunctional cytokine interleukin-6 (IL-6) has
been specifically implicated in aneurysm pathogenesis, con-
tributing to both acute and chronic inflammatory pro-
cesses. A body of circumstantial evidence suggests that
AAAs secrete IL-6 into the circulation. It has been demon-
ilators
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concentrations compared with controls,5-8 and in vitro
tissue culture models revealed that aneurysms actively se-
crete IL-6.9,10
It is plausible that IL-6 may play a far more critical and
insidious role in the long-term fate of the patient with
aneurysm disease. Elevated circulating IL-6 is an indepen-
dent risk factor for future myocardial infarction and cardio-
vascular and all-cause mortality.8,11 This may be relevant
considering that two thirds of patients with AAA die from
cardiovascular causes unrelated to their aneurysm.12
We hypothesized that IL-6 is secreted into the circula-
tion by the aneurysm and, therefore, plasma levels will be
higher downstream to the aneurysm. Because no direct
evidence exists to support this hypothesis, we aimed to
measure circulating IL-6 in vivo from several points within
the aorta in patients with aneurysms.
METHODS
Patients. The study comprised three groups of pa-
tients, 27 with asymptomatic infrarenal aneurysms (AAAs)
and nine with asymptomatic thoracic aneurysms (TA), all
scheduled for elective endovascular aneurysm repair. The
control group consisted of 15 patients undergoing diag-
nostic or interventional angiograms. The indications for
angiograms were uterine artery embolization in 7, iliac and
femoral angioplasty in 4, renal angiogram in 3, and femoral
angiogram in 1. Patients were excluded if there was evi-
dence of acute illness or infection, an active inflammatory
condition, malignancy, or corticosteroid use. All patients
Table I. Demographic and clinical characteristics of subje
TA
n  9 (%)
Demographics
Age, years (range) 74 (62-80)
Male sex 5 (56)
Aneurysm diameter (mm) 57 (44-92)
Current smoker 3 (33)
Ex-smoker 4 (44)
Prevalent chronic diseases†
Hypertension 8 (89)
Ischemic heart disease 4 (44)
Cerebrovascular disease 3 (33)
Diabetes mellitus 2 (22)
COPD 2 (22)
Chronic renal impairment 3 (33)
Medication
Statin 6 (67)
Aspirin 5 (56)
NSAID 1 (11)
TA, Thoracic aneurysm; AAA, abdominal aortic aneurysm; COPD, chronic
*Values for continuous variables are reported as mean (range) with compar
by 2 test.
†Definitions: Hypertension, Chronic treated hypertension; ischemic heart di
artery bypass grafting; cerebrovascular disease, history of transient ischemic a
insulin; COPD, evidence on lung function tests or treatment with bronchod
under treatment with renal physician for chronic renal failure.undergoing aneurysm repair received a general anaesthetic,whereas angiography was performed under local anesthesia.
Patient demographics are listed in Table I. The study was
approved by theWandsworth Local Ethics Committee, and
patients gave written informed consent.
Blood collection. Before endovascular aneurysm re-
pair or angiographic intervention occurred, a size 4F angio-
graphic flush catheter (Cordis, Johnson & Johnson, Miami
Lakes, Fla) was passed into the aorta through a femoral
puncture. Blood was aspirated sequentially from several
points within the aorta: ascending aorta (TA only), arch of
aorta or thoracic aneurysm, descending aorta, proximal
abdominal aorta (AAA and controls only), distal abdominal
aorta, and external iliac artery. Positions were standardized
by using the following anatomic landmarks identified on
fluoroscopy: distal to the aortic valve (ascending aorta),
proximal to the left subclavian artery (arch of aorta), prox-
imal to the diaphragm (descending aorta), L2 lumbar ver-
tebrae (proximal AAA) and L3 lumbar vertebrae (distal
AAA), and distal to bifurcation (common iliac artery). A
peripheral venous sample was also obtained from the ante-
cubital fossa.
Samples were obtained before infusion of radiographic
contrast medium and heparin, collected into ethylenedia-
minetetraacetic acid bottles, and immediately transported
to the laboratory on ice. Samples were centrifuged for 10
minutes at 3000 rpm, and the plasma was stored in aliquots
at –80°C.
Laboratory methods. Plasma samples were analyzed
by a blinded observer in batches after one freeze–thaw
episode. Plasma IL-6 concentrations were measured in
AAA
 27 (%)
Control
n  15 (%) P
(58-91) 50 (32-74) .0001
(100) 3 (20) .0001
(51-100) — —
(30) 5 (33) 0.96
(63) 2 (13) 0.008
(67) 5 (33) 0.017
(48) 0 (0) 0.005
(22) 0 (0) 0.077
(15) 0 (0) 0.2
(22) 0 (0) 0.14
(30) 4 (27) 0.94
(81) 5 (33) 0.0074
(89) 1 (7) .0001
(7) 3 (20) 0.48
uctive pulmonary disease; NSAID, Nonsteroidal anti-inflammatory drugs.
y analysis of variance. Categoric variables expressed as n (%) and compared
istory of angina, heart failure, previous myocardial infarction, or coronary
or cerebrovascular accident, or both; diabetes, controlled by diet, tablet, or
; chronic renal impairment, chronic renal failure on urea and electrolytes orcts*
n
73
27
64
8
17
18
13
6
4
6
8
22
24
2
obstr
isons b
sease, h
ttackduplicate using an enzyme-linked immunosorbent assay
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High-sensitivity C-reactive protein (hs-CRP) was deter-
mined by rate turbidimetry immunoassay (Synchron LX
System, Beckman Coulter, Inc, Fullerton, Calif) as a base-
line for systemic inflammation.
Thrombus content. Thrombus content of the aneu-
rysm was estimated using computed tomography (CT)
imaging. The percentage of the aortic cross-sectional area
that the thrombus occupied was calculated at the level of
maximum thrombus deposition.
Aneurysm surface area. The total surface area of an-
eurysmal aorta was calculated by summing the individual
surface areas of 10-mm volume slices on axial CT scans at a
CT workstation.
Statistical analysis. Categoric variables were com-
pared by a 2 test. Normally distributed data were ex-
pressed as mean  standard error. Nonparametric data
were expressed as median  interquartile range (IQR).
Statistical analysis among the three groups was performed
using one-way analysis of variance (ANOVA). Compari-
sons within groups were performed with repeated measures
ANOVA. An unpaired Student’s t test was used for com-
parison of means and a Mann-Whitney test for comparison
of medians or ranked data. Statistical significance was set at
P  .05. Statistical analysis was performed using Prism 4.0
(GraphPad Software, Inc, San Diego, Calif) and SPSS 12.0
(SPSS, Inc, Chicago, Ill) software.
RESULTS
Aortic interleukin-6. Mean aortic plasma IL-6 con-
centrations (pg/mL) were calculated from samples col-
lected from all positions and were higher overall in patients
with AAAs and TAs compared with controls (AAA, 4.94
0.48; TA, 10.36 3.68; controls 2.65 0.51; P .002).
Table II. Association between arterial interleukin-6 and h
location in patients with thoracic aneurysms, abdominal ao
Aorta location
Interleukin-6 (pg
TA
n  9
AAA
n  27
Ascending 9.61  3.55 —
Arch/TA 9.84  3.48 4.70  0.4
Descending 11.20  3.94 4.73  0.4
Proximal abdomen — 5.00  0.5
Distal abdomen 10.61  3.83 5.09  0.5
Iliac artery 10.53  3.63 5.17  0.4
P .008* .002*
Mean concentration
Aortic 10.36  3.68 4.94  0.4
P .002†
Venous 11.51  4.02 5.34  0.7
P .008†
TA, Thoracic aneurysm; AAA, abdominal aortic aneurysm; hs-CRP, high-s
Results expressed as mean  SEM.
*One-way repeated measures analysis of variance.
†One-way analysis of variance.
‡Unpaired Student’s t test.This relationship was unaltered after adjusting the data forage and sex (P  .002) and also remained significant after
adjusting for 3-hydroxy-3 methyl-glutaryl-coenzyme A
(statin) use.
Within both aneurysm groups, there was a significant
Fig 1. Variation in interleukin-6 (IL-6) concentrations with aorta
position in thoracic aneurysms (TA), abdominal aortic aneurysms
(AAA), and controls. Vertical axis, showing mean plasma IL-6
within the aorta, is interrupted between 5 and 10 pg/mL. Con-
centrations of aortic IL-6 increased significantly throughout the
aorta in patients with TAs (P  .008) and AAAs (P  .002),
corresponding to aneurysm position (repeated measures analysis of
variance). This pattern was not observed in the control group.
Results expressed as mean  SEM.
ensitivity C-reactive protein concentrations and aortic
neurysms, and controls
) hs-CRP (mg/L)
Control
n  15
AAA
n  25
Control
n  12
— — —
2.45  0.50 4.79  0.95 3.65  1.02
2.65  0.54 4.76  0.94 3.62  1.02
2.82  0.59 4.80  0.93 3.69  1.03
2.80  0.59 4.83  0.95 3.65  1.01
2.54  0.47 4.68  0.89 3.52  0.98
.26* .24* .21*
2.65  0.51 4.77  0.93 3.62  1.01
.44‡
2.75  0.64 5.23  1.35 3.65  1.21
.42‡
ity C-reactive protein.igh-s
rtic a
/mL
7
8
1
0
6
8
8
ensitivdifference in IL-6 with aortic position. Elevation in IL-6
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II). In the AAA group, there was a significant rise in IL-6
concentration distal to the aneurysm (P  .002) that fol-
lowed a linear trend (P  .001, post-test for linear trend,
Fig 1). The TA group also demonstrated a rise in IL-6
concentration corresponding to aneurysm position (P 
.008), which corresponded to a linear trend (P  .01).
Within the control group, there were no significant
differences in IL-6 with aortic position and no linear
trend.
The maximum plasma IL-6 level for each aneurysm
patient was ranked according to aorta location. Compari-
son of these ranked data revealed that plasma IL-6 peaked
earlier in the TA group than in the AAA group, correspond-
ing to the anatomic position of the aneurysm (distal de-
scending aorta vs iliac artery, P  .0007). Within the AAA
group, six patients (22%) had aneurysmal extension into the
common iliac arteries. Subgroup analysis of the AAA
group, excluding the iliac aneurysms, did not alter the
pattern of IL-6 with aorta position.
Systemic venous concentrations were significantly
higher in the aneurysm groups (P .008) andmirrored the
arterial levels (Table II).
Aneurysm surface area. Fig 2 displays the linear re-
gression line between mean aortic plasma IL-6 and aneu-
rysm surface area (Spearman’s rank correlation r  0.48,
P  .003). The mean aneurysm surface area in the TA
group, 0.07 m2 (IQR, 0.06 to 0.09) was also significantly
higher than that in the AAA group, 0.03 m2 (IQR, 0.02 to
0.04; P  .0002).
C-reactive protein. There was no significant differ-
ence in hs-CRP throughout the aorta in patients with AAAs
and controls. Arterial and venous concentrations of CRP
were higher in the AAA group, but this did not reach
statistical significance.
The effect of thrombus. The mean thrombus burden
was 56% of aneurysm cross-sectional area (range, 16% to
Fig 2. Correlation between mean aortic plasma interleukin-6
(IL-6) and aneurysm surface area in patients with thoracic and
abdominal aortic aneurysms. The linear regression and 95% confi-
dence interval are shown.83%). Linear regression analysis failed to identify any cor-relation between thrombus and plasma IL-6, or thrombus
and plasma CRP.
DISCUSSION
Aortic aneurysms as a source of circulating
interleukin-6. Explants from AAAs have been to shown
to secrete several cytokines, including tumor necrosis
factor-, interferon-, monocyte chemoattractant pro-
tein-1, and IL-1, IL-6, and IL-8.5,10,13-16 Interleukin-6
has emerged as the principal cytokine consistently associ-
ated with AAA, being secreted in vitro at higher levels than
in both healthy controls and those with occlusive aortic
disease.5,9,10,17,18 Circulating levels of IL-6 have also been
reported to be significantly higher in patients with AAAs
than in controls.5,6 Furthermore, these systemic concentra-
tions have been correlated with aortic diameter in both
patients with aneurysms5,8 and in healthy subjects.7 These
data suggest that IL-6 may play a role in the early biologic
processes of aortic dilatation that eventually leads to aneu-
rysm development.
Jones et al8 suggested that aneurysms secreted IL-6
into the circulation by observing that IL-6 was higher in the
iliac arteries compared with the brachial arteries of patients
with AAA.8 Our results support and strengthen this hy-
pothesis because they are the first, to our knowledge, to be
based on direct measurements from within the aneurysm.
Overall levels of IL-6 were higher in the TAs compared
with the AAAs. Although the mean maximum aneurysm
diameter was higher in the AAAs (64 mm vs 57 mm), the
total extent of aneurysmal disease in terms of surface area
affected was approximately twofold higher in the TA
group. Considering that we have demonstrated a correla-
tion between mean plasma IL-6 and aneurysm surface area,
it is interesting to note that this is the same order of
magnitude difference seen in plasma IL-6 between the two
groups. If the aneurysm does secrete IL-6 into the circula-
tion, then a larger-volume aneurysm will provide a larger
surface area, leading to higher concentrations of circulating
IL-6.
In both the TA and AAA groups, levels of IL-6 were
similar in the preaneurysm and first aneurysm positions.
After this, a significant rise was noted in IL-6 correspond-
ing to the second aneurysm position. In the AAA group the
levels continued to rise, in the TA group they fell, perhaps
because there was only one sample site after the aneurysm
in the AAA group, whereas there were two in the TA group.
The pattern of IL-6 elevation in both aneurysm groups
conformed to a linear trend: IL-6 tended to increase overall
throughout the length of the aorta. These patterns were
not observed in the control group, which did not conform
to a linear trend.
The CRP levels in the present study are within normal
limits, indicating an absence of widespread inflammation.
The elevated IL-6 concentrations observed in the aneurysm
patients are therefore unlikely to simply reflect systemic
inflammation and may be specifically due to the aneurysm.
This hypothesis is further supported by the observation of
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aorta corresponding to aneurysm position.
The IL-6 has several possible sources9 because it is
secreted by numerous cell types found within aneurysms.20
The most obvious candidates are those cells present in the
inflammatory infiltrate associated with the aneurysm wall,
such as macrophages, B and T lymphocytes, and plasma
cells.1 Macrophages and neutrophils have also been identi-
fied in the intraluminal thrombus found within most aneu-
rysms.21 In addition, cells integral to the vascular wall of
aneurysms, including fibroblasts, smooth muscle cells, and
endothelial cells, have also been shown to secrete IL-6.
Interleukin-6 as an independent risk factor for car-
diovascular mortality. Elevated circulating IL-6 has been
identified as an independent risk factor for cardiovascular
and all-cause mortality in elderly populations with cardio-
vascular disease22,23 and for future myocardial infarction in
young, apparently healthy controls.11 In addition, the CC
genotype, which predisposes to higher circulating levels of
IL-6, was associated with a higher risk of cardiovascular and
all-cause mortality in patients with aneurysms.8
Controversy exists about whether this association is a
disease epiphenomenon or causal. It has been suggested
that preclinical atherosclerosis acts as an inflammatory stim-
ulus, with IL-6 a marker rather than cause of disease.11
Conversely, it has been proposed that the relationship with
mortality is not simply explained by the severity of concom-
itant disease, because elevated IL-6 has been associated with
mortality independent of cardiovascular disease severity. 23
Juvonen et al6 reported higher levels of circulating IL-6
in AAA patients compared with those with coronary heart
disease, suggesting that the elevated IL-6 was due to the
aneurysm and independent of any coexisting coronary
heart disease. In addition, Brady et al24 reported a relation-
ship between aneurysm diameter and cardiovascular mor-
tality that was independent of atherosclerotic risk factors.24
This group highlighted the fact that if the aneurysm wall
was a source of IL-6, this could influence myocardial func-
tion, thrombosis, and inflammation.24
Proinflammatory cytokines have negative inotropic ac-
tions,25,26 stimulate sympathetic and renin-angiotensin
systems,23 stimulate a prothrombotic state mediated by
CRP,23 and stimulate matrix metalloproteinases, leading to
destabilization of atherosclerotic plaques. Because IL-6 is
associated with numerous conditions characterized by tis-
sue injury, this pathophysiologic mechanism may explain
the excess risk of mortality associated with increasing circu-
lating levels of inflammatory markers.23 Elevated systemic
IL-6 is therefore a plausible contributing factor in the high
cardiovascular mortality observed in patients with AAA at
all stages of the disease.12,27,28
Whether the elevated IL-6 identified in patients with
TAs leads to a higher incidence of cardiovascular death than
in patients with AAAs is a matter of conjecture. Bearing in
mind perioperative mortality is higher in endovascular re-
pair of TAs compared with AAAs, long-term survival rates
of patients who have undergone endovascular repair of TAs
are worse than that of AAAs. The largest series quote 1-yearmortality of about 18% to 20%29,30 for TA and 51% at 5
years,30 compared with 1-year mortality of 7.4% after en-
dovascular repair of AAA and 26% at 4 years.31 Most deaths
in both groups are due to acute cardiovascular events and
are not aneurysm related.
Clinical relevance. Anecdotal evidence from the UK
Small Aneurysm Trial supports our hypothesis. Patients
who underwent early surgery had a 7.2% survival advantage
at 8 years over those under surveillance, possibly owing to
reduced temporal exposure to aneurysm-derived IL-6.12 In
addition, despite low perioperative mortality, the risk of
death after endovascular repair of large AAA is approxi-
mately 8% at 1 year, with almost all deaths resulted from
cardiovascular causes.31 It remains to be seen whether
aneurysm repair actually reduces circulating IL-6 concen-
trations and whether exclusion of the aneurysm by endo-
vascular means would reduce circulating IL-6. This is
clearly a key question and a prospective study is underway
looking at this.
Statins are associated with a reduction in cardiovascular
morbidity and mortality in patients with aneurysms,32 and
although their mechanism of action is almost certainly
pleiotropic, they have been shown to reduce circulating
IL-6.33,34 As such, they form an integral part of the risk
factor modification regimen that must complement the
treatment of all patients with aneurysmal disease. This
includes smoking cessation and the use of antihypertensive
and antiplatelet medications.
Study limitations and considerations. As a major
determinant of the acute phase response, IL-6 may be se-
creted in response to any stimuli resulting in tissue injury. 4,35
The aneurysm groups received general anesthesia, which
may account for an acute rise in inflammatory markers.
Evidence shows, however, that circulating IL-6 and CRP
concentrations are similar to preoperative levels until at
least 1 hour into a major operation,36 and in the present
study, blood was collected at the beginning of the proce-
dure.
The principal limitation of the study was finding a
suitable control group, matched for age, sex, and comor-
bidities, undergoing elective invasive vascular procedures
allowing access to aortic circulation. However, when the
data were corrected for age and sex, the presence of an
aneurysm still had a significant effect on mean plasma IL-6
concentrations within the aorta.
As previously mentioned, certain drugs may influence
IL-6 levels. Statins, in particular, have been shown to
reduce IL-6 production from carotid plaques.34 However,
when the data were corrected for statin use, as well as age
and sex, the relationship between mean plasma IL-6 and
presence of aneurysm was not significantly affected. Other
drugs more prevalent in the aneurysm groups include aspi-
rin and antihypertensives such as angiotensin-converting
enzyme inhibitors and -blockers. In common with statins,
there is good evidence that these drugs have a direct
anti-inflammatory effect and reduce levels of IL-637,38 and
therefore we would not expect their effect to negate our
findings.
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mented heart disease, and coronary plaques have been
shown to express IL-6.39 However, in contrast to acute
coronary events in which circulating levels are elevated,40 in
quiescent coronary disease, as found in the aneurysm
groups, circulating levels of IL-6 have been reported to be
similar to that of healthy controls.6
Another potential criticism is that other manifestations
of atherosclerotic burden such as peripheral artery disease
could account for the elevated IL-6 observed. However,
the proportion of patients with symptomatic peripheral
artery disease was much higher in the control group (con-
trol, 27%; AAA, 15%; TA, 0%). Althoughmore nonsmokers
were in the control group, current smoking status has been
shown to influence circulating IL-6,11 and this was similar
in all groups (control, 30%; AAA, 33%; TA, 33%).
CONCLUSION
The present study provides evidence supporting the
theory that the aneurysm wall is a source of circulating
IL-6. In addition to its role in aneurysm pathogenesis,
aneurysm-derived IL-6 may stimulate distant systemic ac-
tions. Because circulating IL-6 has been identified as an
independent risk factor for mortality, it is reasonable to
suggest that the biologic effect of aneurysms may be more
far-reaching and insidious regarding serious implications
for cardiovascular health than the well-documented mor-
tality associated with rupture and repair. It remains to be
seen whether aneurysm repair reduces circulating levels of
IL-6.
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